## 9 Application of the TFME Technique in the Analysis of Organic Compounds
\begin{table}
\begin{tabular}{c c c c c c c c c} \hline \hline
**Matrix** & **Analyte** & **Sorption Phase** & **Detection** & **LOD** & **Recovery** & **RSD** & **Ref.** \\ \hline \multirow{8}{*}{Urine} & \multirow{8}{*}{Estrogens} & MIL-53(Al)/PVDF & \multirow{8}{*}{HPLC-FLD} & \multirow{8}{*}{0.005–1 ng mL\({}^{-1}\)} & \multirow{8}{*}{80–103} & \multirow{8}{*}{\(\leq\)11.4} & [72] \\  & & MIL-53(Fe) /PVDF & \multirow{8}{*}{0.005–1 ng mL\({}^{-1}\)} & \multirow{8}{*}{80–103} & \multirow{8}{*}{\(\leq\)11.4} & [72] \\  & & MIL-100(Fe) /PVDF & \multirow{8}{*}{UG-66(Zr) /PVDF} & & & & \\  & & Ui-66(Zr) /PVDF & & & & & \\ \cline{2-8}  & Urinary & \multirow{2}{*}{Urine} & \multirow{2}{*}{-} & HPLC-QQ/MS & 0.04–0.09 ng mL\({}^{-1}\) & - & - & [177] \\  & androgens & & & QqQ/MS & & & & \\ \cline{2-8}  & Caffe & \multicolumn{2}{c}{ZF-} & HPLC-UV & \multirow{2}{*}{89–93} & \multirow{2}{*}{[84]} \\  & & 8/LDH/GO/PVDF & & & & & \\ \cline{2-8}  & Aldehydes & MOF-199/PS & HPLC-VWD & 4.2–17.3 nmol L\({}^{-1}\) & 82–112 & 2–13 & [76] \\ \cline{2-8}  & Non-steroidal & \multirow{2}{*}{CY-GO-LDH} & HPLC-UV & 0.25 ug L\({}^{-1}\) & - & 6 & [82] \\  & anti-inflammatory drugs & & & & 0.14 ug L\({}^{-1}\) & & & \\  & & & in water & & & & \\  & & LDH/GO/PVDF & HPLC-UV & 0.23 ug L\({}^{-1}\) & & 7 & \\  & & & & in urine & & & \\  & & & & 0.57 ug L\({}^{-1}\) & & 7 & \\  & & & plasma samples & & & & \\ \hline Benzodiazepepines & C18/glue & HPLC-MS & 0.05–0.15 ng mL\({}^{-1}\) & - & 5–7 & [25] \\ \hline Codeine & \multirow{2}{*}{Actamiprid} & \multirow{2}{*}{APtamer/cellulose} & \multirow{2}{*}{ESI-IMS} & \multirow{2}{*}{3.7 ng mL\({}^{-1}\)} & \multirow{2}{*}{87–91} & \multirow{2}{*}{2–6} & [106] \\  & & & & & & & \\ \hline Methamphetamine & \multirow{2}{*}{\begin{tabular}{c} Artamer/CDs/ \\ cellulose \\ \end{tabular} } & \multirow{2}{*}{ESI-IMS} & \multirow{2}{*}{0.45 ng mL\({}^{-1}\)} & \multirow{2}{*}{87–108} & \multirow{2}{*}{\(<\)8} & [107] \\ \cline{2-8}  & & & & 3.8 ug L\({}^{-1}\) & & \\  & & & for indomethacin & & & \\  & & & & 7.2 ug L\({}^{-1}\) & & & \\  & & & & for diclofenac & & \\ Urine & Nonsteroidal anti-inflammatory drugs & \multirow{2}{*}{p-PIL-AcO} & \multirow{2}{*}{LC-MS/MS} & \multirow{2}{*}{72–95} & \multirow{2}{*}{1–13} & \multirow{2}{*}{[115]} \\  & drugs & & & 9.4 ug L\({}^{-1}\) & & \\  & & & & for ketoprofen & & \\  & & & & 15.7 ug L\({}^{-1}\) & & \\  & & & & for napore & & \\  & & & & 5.1 ug L\({}^{-1}\) & & \\  & & & & for ibuprofen & & \\ \hline \multicolumn{8}{c}{Nonsteroidal} & \multirow{8}{*}{MOF-5} & \multirow{8}{*}{HPLC-UV} & \multirow{8}{*}{94–108} & \multirow{8}{*}{4–6} & [143] \\  & anti-inflammatory drugs: & & & & & \\ \cline{2-8}  & naproven, & & & & & \\ \cline{2-8}  & aspirin, tolmen, & & & & & \\ \cline{2-8}  & celecoxib & & & & & \\ \cline{2-8}  & Endocrine-disrupting & \multirow{2}{*}{DES} & LC-MS/MS & 0.01–1.15 ng mL\({}^{-1}\) & - & 3–10 & [178] \\  & compounds & & & & & \\ \hline Tramadol & Ni(DMG)2-NiO-Cell & HPLC-UV & 0.1–1.0 ng mL\({}^{-1}\) & 86 & 6–8 & [156] \\ \hline \multicolumn{8}{c}{Carvedilol} & \multirow{2}{*}{g-C3N4/N6 NC} & \multirow{2}{*}{FS} & \multirow{2}{*}{1.0 ng mL\({}^{-1}\)} & \multirow{2}{*}{83} & \multirow{2}{*}{4} & [158] \\  & blocker & & & & & \\ \hline \multicolumn{8}{c}{Fentanyl,} & \multirow{2}{*}{Octyl-} & \multirow{2}{*}{HPLC-} & \multirow{2}{*}{4.0–17.4 ng mL\({}^{-1}\)} & \multirow{2}{*}{43–76} & \multirow{2}{*}{\(<\)15} & [157] \\  & methadone, zolpidem & & cyanopropyl/PAN & & & \\ \hline \multirow{8}{*}{Urine} & \multirow{2}{*}{Fluoxetine} & GO/CS & \
\begin{tabular}{c} HPLC-UV- \\ Vis \\ \end{tabular} & \multirow{2}{*}{1.0 ng mL\({}^{-1}\)} & \multirow{2}{*}{82} & \multirow{2}{*}{\(\leq\)9} & [152] \\ \cline{2-8}  & Tricyclic antidepressants & Ni-Co MOFs-PAN & HPLC-UV & 0.06–0.3 ug L\({}^{-1}\) & 91–100 & \(<\)5 & [153] \\ \cline{2-8}  & \multirow{2}{*}{Biogenic} & \multirow{2}{*}{HLB/PAN} & \multirow{2}{*}{
\begin{tabular}{c} UPLC- \\ MS/MS \\ \end{tabular} } & \multirow{2}{*}{36–75} & \(<\)9} & [179] \\ \cline{1-1} \cline{5-5}  & & & & & & \\ \hline \end{tabular}
\end{table}